Xigen S.A.

https://www.xigenpharma.com

Xigen, a Swiss biopharmaceutical company founded as a spin-off of the Centre Hospitalier Universitaire Vaudois (CHUV), specializes in the research and development of innovative therapeutic peptides with a focus on inflammatory diseases. The Company’s technology has enabled the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to intracellular targets in disease relevant cell types. Xigen’s lead compound Brimapitide (XG-102) is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease. *

	Start	2002-01-14 splitoff
	Predecessor	CHUV Centre Hospitalier Universitaire Vaudois (University Hospital Lausanne)
	Industry	anti-inflammatory drug
	Industry 2	brimapitide (XG-102)
	Person	Bonny, Christophe (Enterome 201609– CSO before Bicycle Therapeutics + Xigen + Univ Hospital Lausanne)

	Region	Epalinges VD
	Country	Switzerland
	Street	4 Route de la Corniche
	City	1066 Epalinges VD
	Tel	+41-21-321-1080
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Xigen S.A.

[1] Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]